PRAGUE, Czech Republic, June 1, 2016 /PRNewswire/ -- The 55th Annual Particle Therapy Co-Operative Group (PTCOG) conference came to a successful conclusion on May 28, 2016 in Prague.
Medical investment and hospital management company XKmed served as a silver sponsor of the conference, the only supporting company from China that was present.
The conference assembled various medical experts from across the world to share technical and clinical results about proton therapy for pediatric oncology, head and neck neoplasm, breast cancer and central nervous system neoplasms.
At the same time, the study of biology, adaptive proton therapy, image-guided proton therapy and dosimetry were also introduced to the audience.
The conference served as an ideal platform for Chinese medical institutions and experts to showcase the advances in Chinese medical science, including "Made in China" particle therapy equipment, "Invested in China", which refers to international medical companies with Chinese capital investment, Chinese proton heavy ion clinic treatment, and other cutting-edge medical technologies.
Delegates from Shanghai Proton Heavy Ion Hospital, the Chinese Academy of Sciences, XKmed and other Chinese medical institutions attended to the conference, in addition to various Chinese radiation experts.
A representative from Shanghai Proton Heavy Ion Hospital shared the results from an academic study of nasopharyngeal carcinoma treatment, and also demonstrated the achievement of the clinic's treatment. Among the exhibitors, the proportion of Chinese capital investment holding foreign companies was greater than in previous years, with XKmed CEO, Mr. Gu Xin commenting, "This is just the beginning of 'China Power.'''
The Particle Therapy Co-operative Group is a non-profit organisation for those interested in proton, light ion and heavy charged particle radiotherapy. PTCOG is an annual medical conference, which in the past four years has been held in Japan, the United States, Korea and Germany.
Founded in 2009, XKmed is a specialized organisation engaging in the fields of medical investment and hospital operational management. In addition, XKmed concentrates its resources on sectors such as Proton/ Heavy Ion Therapy, early cancer detection/screening, and cancer recurrence treatment. Meanwhile, XKmed has developed two significant medical journey brands named "Journey to regain life & Journey to embrace health."